Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes

Table 1 Baseline parameters, including body and liver weights, as well as post-treatment plasma metabolic markers of lean control (CkC), untreated db/db (DbC) and db/db mice treated with EMPA (DbE)

Parameter	ANOVA	CkC	DbC	DbE
Parameter	P value	(11)	(12)	(13)
Body weight
Pre-treatment body weight (g)	0.001	18.9 ± 0.2	46.1* ± 0.7	45.4^§ ± 0.7
Post-treatment body weight (g)	0.001	19.2 ± 0.3	53.6* ± 1.0	53.5^§ ± 0.7
Delta (g)	0.001	0.17 ± 0.29	7.50* ± 0.76	8.32^§ ± 0.50
% Increase in body weight	0.001	0.7 ± 1.6	13.8* ± 1.3	15.5^§ ± 0.9
Hepatic
Liver weight (mg)	0.001	835 ± 37	2460*^,† ± 92	2031^§ ± 72
Triglycerides (nmol g⁻¹)	0.001	15 ± 3	43* ± 5	37^§ ± 4
Plasma
Cholesterol (mg dl⁻¹)	0.001	76 ± 5	145* ± 3	148^§ ± 6
Triglycerides (mg dl⁻¹)	0.001	126 ± 9	310* ± 18	301^§ ± 20
Alanine aminotransferase (U l⁻¹)	0.001	27 ± 2	78* ± 5	69^§ ± 8

Values are mean ± SE. Post-hoc comparisons; P < 0.05 for * CkC vs DbC; ^† DbCvs DbE; and ^§ CkC vs DbE. Sample sizes are noted in parentheses

ISSN: 1475-2840